Search clinical trials for: HIV-1 immunogen, incomplete Freund's adjuvant

Total 65122 results

Merck Sharp & Dohme LLC

Terminated

MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)

HIV-1 Infection
University Hospital, Strasbourg, France

Unknown

Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation

HIV-1 Infection

France
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

HIV-1 Infection
The HIV Netherlands Australia Thailand Research...
Chulalongkorn University; UMC St. Radboud, Nijmegen, The Netherlands

Completed

Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children

HIV-1 Infections

Thailand
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Canada, United States, Puerto Rico, Spain, United Kingdom, France, Portugal, Netherlands, Belgium, Italy, Australia, Austria, Germany, Switzerland
Hospitales Universitarios Virgen del Rocío

Completed

Etravirine Plus 2 Analogs in HIV-infected Patients

HIV-1-infection

Spain
Abbott

Completed

Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China

HIV-1 Infections

China
International Partnership for Microbicides, Inc.

Completed

A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method

HIV Infections

South Africa, Tanzania
Penumbra Inc.

Terminated

PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase (PRONTO)

Intraventricular Hemorrhage | Intracerebral Hemorrhage | Brain Hemorrhage

United States
Bayside Health
The Peter Doherty Institute for Infection and Immunity

Recruiting

Optimising Cohorts for HIV Cure Interventions (HI-ART)

HIV-1-infection

Australia
Peking Union Medical College Hospital

Not yet recruiting

A Real-world Study of Lamivudine and Dotiravir Sodium Tablets in the Treatment-naïve HIV-1 Infected Patients

HIV-1-infection
Societa' Italiana Di Malattie Infettive E Tropicali

Recruiting

Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study) (EDOLAS)

HIV-1-infection

Italy
Fundación Pública Andaluza para la Investigación...

Not yet recruiting

Impact of V106I on Resistance to Doravirine (V106IFC)

HIV-1-infection
Fundación Huésped
ViiV Healthcare; Federal University of Bahia

Recruiting

Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 (DOLCE)

HIV-1-infection

Brazil, Argentina
United BioPharma

Not yet recruiting

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

HIV-1-infection
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
David Ho
Bill and Melinda Gates Foundation; International AIDS Vaccine Initiative; The...

Completed

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

HIV-1-infection

United States
United BioPharma

Completed

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

HIV-1 Infection

Taiwan
Association de Recherche en Virologie et Dermatologie

Completed

Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES) (LAMRES)

HIV-1-infection

France
University of Colorado, Denver

Completed

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

HIV-1-infection

United States
NEAT ID Foundation
ViiV Healthcare

Completed

An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N (WISARD)

HIV-1-infection

Spain, Belgium, France, Germany, Italy, United Kingdom
Imperial College London

Active, not recruiting

Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens (EAVI2020_01)

HIV-1-infection

United Kingdom
CytoDyn, Inc.

Active, not recruiting

PRO 140 in Treatment-Experienced HIV-1 Subjects

HIV-1-infection

United States
United BioPharma
National Taiwan University Hospital; Kaohsiung Medical University Chung-Ho... and other collaborators

Completed

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

HIV-1 Infection

Taiwan
Mylan Inc.
ViiV Healthcare

Completed

Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

HIV-1-infection

Canada
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

France, Spain, Germany, United Kingdom, United States, Puerto Rico, Belgium, Canada, Italy, Dominican Republic
Gilead Sciences

Completed

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

HIV-1-infection

United States, Puerto Rico, France, Germany, Austria, Canada
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects

HIV-1 Infection

China
Kirby Institute

Terminated

Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients (HSCT-HIV)

HIV-1 Infection

Australia
University of Washington
National Institute of Mental Health (NIMH); Bill and Melinda Gates Foundation; Kenya Medical Research Institute and other collaborators

Completed

The Partners Scale-Up Project

HIV-1-infection

Kenya
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (BRAAVE 2020)

HIV-1 Infection

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Options for Second-Line Effective Combination Therapy (SELECT) (SELECT)

HIV-1 Infection

Peru, Kenya, Malawi, Brazil, South Africa, Zimbabwe, India, Thailand, Tanzania
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

HIV-1 Infection

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

HIV-1 Infection

United States, Puerto Rico
Azienda Ospedaliera Universitaria Integrata Verona

Completed

Short Cycle Therapy in ART Regimens Containing Rilpivirine: Assessment of Patients' Satisfaction

HIV-1-infection

Italy
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaborators

Completed

A Study of the Safety and Antiretroviral Activity of 3BNC117

HIV-1 Infection

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)

HIV-1 Infection

Germany, Romania
Erasmus Medical Center

Completed

LRAs United as a Novel Anti-HIV Strategy. (LUNA)

HIV-1-infection

Netherlands
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Janssen-Cilag Ltd.

Completed

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

HIV-1 Infection

Spain, France
Gilead Sciences

Completed

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

HIV-1 Infection

United States
Gilead Sciences

Terminated

Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus

HIV-1-infection

Uganda, Zimbabwe
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, France, Germany, United Kingdom, Italy, Canada, Australia, Belgium, Puerto Rico, Dominican Republic
Radboud University Medical Center

Terminated

Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen (PRADAII)

HIV-1 Infection

Netherlands, Germany
Gilead Sciences

Completed

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

HIV-1 Infection

Spain, United Kingdom, France, Italy, Belgium
Gilead Sciences

Completed

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

United States
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

HIV-1 Infection

United States, United Kingdom, Canada, France, Italy, Puerto Rico, Belgium
Gilead Sciences

Completed

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

HIV-1 Infection

Russian Federation, United States, Thailand, Uganda, Puerto Rico, Dominican Republic
United BioPharma

Withdrawn

the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

HIV-1 Infection
Azienda Ospedaliera Universitaria Senese
Catholic University of the Sacred Heart; Ospedale Policlinico San Martino; Azienda... and other collaborators

Unknown

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen (DOBINeuro)

HIV-1-infection

Italy
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, United Kingdom, Switzerland, Germany, Canada, France, Belgium, Puerto Rico

3

Subscribe